Kannan C, Akbar M, Begum F, Dwarakanathan A, Burke G
Clin Endocrinol (Oxf). 1976 Jul;5(4):331-40. doi: 10.1111/j.1365-2265.1976.tb01962.x.
TSH and prolactin secretory patterns in thyroid disease have generally been reported as concordant. We studied TSH and prolactin responses to TRH infusion (500 mug) in euthyroid individuals previously treated for thyrotoxicosis with 131I or antithyroid drugs. The 131I-treated group (seven men, twenty women) had been clinically and biochemically euthyroid (normal serum thyroxine and triiodothyronine levels) for 6 months to 4-5 years (kappa +/- SD = 17-1 +/- 4-1 months). Based on maximal TSH increment (deltaTSH), three patient groups were identified: Group 1 [normal deltaTSH, n = 6]: delta prolactin was normal in two, blunted in one and exaggerated in three. Group 2 (exaggerated TSH response, n = 8): delta prolactin was normal in two, blunted in one and exaggerated in five. Group 3 (TSH nonresponders, n = 13): delta prolactin was normal in five, blunted in three, and exaggerated in five. Eleven patients (three men, eight women) were studied after 6 months antithyroid-drug treatment. All were clinically and biochemically euthyroid. All but one showed a blunted TRH-TSH response. All three men showed an exaggerated delta prolactin as did four of eight women. Three women showed a blunted delta prolactin and in one, delta prolactin was normal. Thus, TRH-induced TSH and prolactin response patterns in treated thyrotoxicosis are not uniformly concordant, and, while a blunted or absent TSH response commonly persists long after euthyroidism has been restored, this is most frequently accompanied by a normal or exaggerated prolactin response.
甲状腺疾病中促甲状腺激素(TSH)和催乳素的分泌模式通常被报道为一致的。我们研究了曾用131I或抗甲状腺药物治疗过甲状腺毒症的甲状腺功能正常个体对促甲状腺激素释放激素(TRH,500微克)输注的TSH和催乳素反应。131I治疗组(7名男性,20名女性)在临床和生化指标上甲状腺功能正常(血清甲状腺素和三碘甲状腺原氨酸水平正常)已达6个月至4 - 5年(均值±标准差 = 17.1±4.1个月)。根据TSH最大增加值(ΔTSH),确定了三组患者:第1组[正常ΔTSH,n = 6]:2例催乳素增加值正常,1例减弱,3例增强。第2组(TSH反应增强,n = 8):2例催乳素增加值正常,1例减弱,5例增强。第3组(TSH无反应者,n = 13):5例催乳素增加值正常,3例减弱,5例增强。11例患者(3名男性,8名女性)在接受6个月抗甲状腺药物治疗后接受了研究。所有患者在临床和生化指标上均甲状腺功能正常。除1例外,所有患者的TRH - TSH反应均减弱。3名男性和8名女性中的4名催乳素增加值增强。3名女性催乳素增加值减弱,1名女性催乳素增加值正常。因此,在治疗后的甲状腺毒症中,TRH诱导的TSH和催乳素反应模式并非始终一致,而且,虽然在甲状腺功能恢复正常后很长时间内TSH反应减弱或缺失的情况通常持续存在,但这最常伴随着催乳素反应正常或增强。